跳至主要内容
临床试验/NCT00003737
NCT00003737已完成2 期

A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 1999年1月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Response (complete response, very good partial response, or partial response)

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.

详细描述

OBJECTIVES:

  • Determine the response rate to rebeccamycin analogue in children with relapsed or refractory neuroblastoma.
  • Determine the toxicity of this drug in these patients.
  • Identify and establish in vitro biologic correlates of clinical responses and toxicity of this drug in these patients.

OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Response (complete response, very good partial response, or partial response)

Freedom from progression

Time to treatment failure

次要结局

  • Toxicity

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验